期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | PATHOLOGY LetPub Score 6.3
50 ratings
Rate
Reputation 7.6 Influence 5.1 Speed 7.0 | ||||||||||||||||
期刊簡稱 | PATHOLOGY | ||||||||||||||||
ISSN | 0031-3025 | ||||||||||||||||
E-ISSN | 1465-3931 | ||||||||||||||||
h-index | 57 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 2.80%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://journals.lww.com/pathologyrcpa/Pages/default.aspx | ||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/PAT | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Lippincott Williams and Wilkins Ltd. | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | AUSTRALIA | ||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||
創刊年 | 1969 | ||||||||||||||||
每年文章數 | 91每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 16.73% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0031-3025%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[PATHOLOGY] 的評論 | 撰寫評論 |
作者: 四风丹山 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-13 19:32:04 評論於 Is it a direct rejection or is there a process of being Under Review?(0) 讚! | 四风丹山 |
作者: 宗室芳蔼 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-12 16:35:39 評論於 Review speed: 1.0 | Submission hit rate: 25.0 Emphasized research direction: Experience sharing on renal ischemia-reperfusion Submitted on 2022.05.21, rejected on 2022.06.11, response content: I regret to inform you that, after having been assessed by a member of the Editorial Board, it has been recommended that your manuscript be returned to you(0) 讚! | 宗室芳蔼 |
作者: 宗室芳蔼 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-11 17:38:22 評論於 Review speed: 1.0 | Submission success rate: 25.0 Emphasized research direction: Experience sharing on renal ischemia-reperfusion Date of submission: May 21, 2022 Date of rejection: June 12, 2022 Response: I regret to inform you that, after having been assessed by a member of the Editorial Board, it has been recommended that your manuscript be returned to you(0) 讚! | 宗室芳蔼 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 14:01:09 評論於 Research subject/experimental conditions/some kind of experimental treatment/experimental conclusions and other elements(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 10:54:32 評論於 The title of the paper should be concise, not too long. The shorter the better, avoiding unnecessary words as much as possible while accurately reflecting and clearly expressing the most important specific content. Shorter paper titles generally have higher citation rates(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 19:53:06 評論於 What to Do When the Article Title is Too Long?(0) 讚! | 北国博达 |
作者: 八坂篷蔚 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 09:31:44 評論於 What key points should be included in an article title?(0) 讚! | 八坂篷蔚 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us